
How everyone on Medicare could end up paying for the pricey new Alzheimer's drug
CNN
The controversial new drug for Alzheimer's disease, Aduhelm, is priced at $56,000 a year for treatment -- but Alzheimer's patients won't be the only ones shouldering the cost.
All of Medicare's roughly 60 million enrollees will likely see their premiums rise to cover the new medication, experts say -- and the burden will also fall to federal and state governments and, therefore, to taxpayers.More Related News

President Donald Trump issued a stark threat to defense contracting companies on Wednesday, saying he would seek to limit stock buybacks and executive salaries unless they improve their delivery of weapons systems to the US military hours before saying he’d decided to substantially increase the defense budget.












